ArticleJournal of translational medicine2026
Targeting neuropilin-1 and neutralizing interleukin-6 inhibits cancer stem cell formation in bladder cancer cells.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder urothelial carcinoma (BLCA) remains a clinical challenge because of its high recurrence rate and the persistence of cancer stem cells (CSCs) within the tumor microenvironment (TME). Neuropilin-1 (NRP1) is recognized as a key orchestrator of epithelial–mesenchymal transition (EMT) and stemness in several malignancies; however, its specific mechanism in driving BLCA aggressiveness and CSC maintenance has not been fully elucidated. This study aimed to characterize the regulatory role of NRP1 in bladder cancer progression and identify potential therapeutic options.
methodsThe clinical significance of NRP1 was first assessed using TCGA patient datasets and tissue microarrays. The functional roles of NRP1 were determined through CRISPR/Cas9-mediated knockout, shRNA-mediated knockdown, and overexpression of NRP1 in the T24 and 5637 cell lines. Bulk RNA sequencing and GSEA were utilized to identify downstream pathways, and ELISA and Western blotting were used to validate signaling interactions. Finally, a synergistic therapeutic strategy was tested using a subcutaneous xenograft nude mouse model.
resultsHigh NRP1 expression was significantly associated with advanced tumor stage, chemoresistance, and poor overall survival in patients with BLCA. Mechanistically, NRP1 regulated the IL-6–STAT3 signaling axis; NRP1 depletion significantly reduced IL-6 secretion and phosphorylated STAT3 levels, thereby impairing sphere formation and EMT features. Conversely, exogenous IL-6 treatment rescued the CSC phenotype in NRP1-deficient cells. Clinically, NRP1 expression strongly correlated with IL-6 and STAT3 levels, and patients with high expression of NRP1 and IL-6 had significantly worse survival outcomes, identifying NRP1–IL-6 coexpression as a novel prognostic biomarker in BLCA. Based on these findings, we demonstrated that dual targeting with the NRP1 inhibitor EG00229 and the IL-6-neutralizing antibody siltuximab synergistically suppressed CSC self-renewal and inhibited tumor growth in vivo.
conclusionsThis study provides a comprehensive characterization of the NRP1–IL-6–STAT3 axis as a fundamental driver of bladder cancer stemness. Our findings establish a foundational mechanistic proof-of-concept for a dual-targeting approach. By simultaneously inhibiting NRP1 and neutralizing IL-6, we demonstrated profound suppression of tumor-initiating capacity and CSC self-renewal. This strategy offers significant translational potential for improving clinical outcomes and overcoming therapeutic resistance in patients with aggressive BLCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.